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OBJECTIVE— Diabetes is an independent risk factor for heart failure, whereas the relation
between heart failure and abnormal glucose regulation (AGR) needs further evaluation. We
studied this combination in the Reykjavı´k Study.
RESEARCH DESIGN AND METHODS— The Reykjavı´k Study, a population-based
cohort study during 1967–1997, recruited 19,381 participants aged 33–84 years who were
followed until 2002. Oral glucose tolerance tests and chest X-rays were obtained from all
participants. Cases were defined in accordance with World Health Organization criteria for type
2 diabetes or AGR (impaired glucose tolerance or impaired fasting glucose) and European Society
of Cardiology guidelines for heart failure.
RESULTS— The overall prevalence of type 2 diabetes and heart failure was 0.5% in men and
0.4% in women, while AGR and heart failure were found in 0.7% of men and 0.6% of women.
Among participants with normal glucose regulation, heart failure was diagnosed in 3.2% com-
pared with 6.0 and 11.8% among those with AGR and type 2 diabetes, respectively. The prev-
alence of type 2 diabetes in the age-group 45–65 years increased in both sexes during the period
(P for trend 0.007). The odds ratio was 2.8 (95% CI 2.2–3.6) for the association between type
2 diabetes and heart failure and 1.7 (1.4–2.1) between AGR and heart failure.
CONCLUSIONS— There is a strong association between any form of glucometabolic per-
turbation and heart failure. Future studies in this field should focus on all types of glucose
abnormalities rather than previously diagnosed diabetes only.
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T ype 2 diabetes, a disease of increas-ing prevalence, is a risk factor forheart failure (1,2). Poor glucometa-
bolic control, as reflected by a high
HbA1c, increases the risk of developing
heart failure (3). Diabetic patients are
more prone to develop heart failure dur-
ing an ischemic event, despite compara-
ble size of myocardial injury, and their
prognosis is more unfavorable than that
in nondiabetic patients (4).
The prevalence of heart failure com-
bined with diabetes was 10 and 15%, re-
spectively, among elderly Italians.
Moreover, a higher proportion of patients
with than without heart failure developed
diabetes over time (5). Although there are
reports on the relationship of either dia-
betes or impaired glucose tolerance and
heart failure (6,7), the association of the
total spectrum of glucose abnormalities
and heart failure, as well as the prevalence
and risk factors for heart failure, has, to
our knowledge, not been studied in a
large epidemiological study.
The Reykjavı´k Study is a population-
based study that included glucose toler-
ance tests for almost every participant.
The present study reports on the preva-
lence of glucose abnormalities and heart
failure and their combination in this
population.
RESEARCH DESIGN AND
METHODS— All inhabitants in the
Reykjavı´k metropolitan area at 1 Decem-
ber 1966 and born 1907–1935 were in-
vited to participate in the study, as
previously reported (8). Those who par-
ticipated (n  19,381) were divided into
groups according to date and year of
birth. They were subsequently attending
the study at six time intervals (between
1967 and 1997). Patients aged 50–65
years were represented at all occasions,
which allowed for a comparison of prev-
alence over time. The case subjects in this
study were participants with a diagnosis
of type 2 diabetes, abnormal glucose reg-
ulation (AGR), and/or heart failure at their
first visit to the Reykjavı´k Study, and the
prevalence groups were composed as
such. The remaining participants served
as control subjects, and data from their
first visit were used for comparative anal-
ysis. Follow-up was until 2002. Atten-
dance rate varied between 65 and 77%,
declining somewhat over time. Alto-
gether, 9,323 men and 10,058 women at-
tended at least one visit.
Before the first visit, the participants
answered a standardized questionnaire
regarding a number of health-related fac-
tors (8,9). A medical examination was
performed that included height, weight,
BMI (kg/m2), blood pressure, electrocar-
diogram (ECG), and a chest X-ray (car-
diomegaly defined as heart size 550
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ml/m2 for men and 500 ml/m2 for
women) (10). Each participant under-
went an oral glucose tolerance test
(OGTT; 50 g glucose in 250 ml water) at
each visit until 1990. Blood glucose (in
milligrams per deciliter) was determined
before (fasting) and 1.5 h after the glucose
load, first by means of a chemical method
and then changing to a hexokinase enzy-
matic method. Following a protocol
amendment in 1990, the investigation of
the glucometabolic state was based on
fasting serum glucose (11). Participants
gave their informed consent, and the Na-
tional Bioethics Committee approved the
study, as did the Data Protection Authority.
Definitions of heart failure and
glucose status
Heart failure was defined according to the
European Society of Cardiology guide-
lines as the combination of at least two
symptoms (dyspnea, tiredness, or ankle
edema) and one objective evidence of car-
diac engagement, as disclosed by the ECG
(Q-wave myocardial infarction according
to MONICA [Monitoring Cardiovascular
Disease] criteria [9], left bundle branch
block, or left ventricular hypertrophy) or
the chest X-ray (pulmonary congestion,
cardiomegaly, or lef t ventr icular
enlargement).
Glucometabolic abnormalities were
categorized as type 2 diabetes (fasting se-
rum glucose 7.0 mmol/l [126 mg/dl]
or OGTT serum glucose 11.1 mmol/l
[200 mg/dl]) or AGR (newly diagnosed
impaired glucose tolerance or impaired
fasting glucose; fasting serum glucose
6.1– 6.9 mmol/l [110 –126 mg/dl] or
OGTT serum glucose 7.8–11.0 mmol/l
[140 –200 mg/dl]). These conditions
were defined according to information
from the questionnaire or as newly diag-
nosed type 2 diabetes or AGR based on
OGTT or, from 1990, fasting serum
glucose.
For risk description, participants
were divided into four groups: group 1,
participants with glucometabolic abnor-
malities and heart failure; group 2, partic-
ipants with glucometabolic abnormalities
only; group 3, participants with heart fail-
ure only; and group 4, participants free of
glucometabolic abnormalities and heart
failure.
Statistical analysis
Prevalence was defined as the number of
participants with type 2 diabetes or AGR
or heart failure at their first study visit
divided by the total number of partici-
pants in the Reykjavı´k Study. Prevalence
was stratified by age and sex. Time trends
for prevalence of the cases and reference
groups are presented in 10-year strata
from the time of diagnosis. The effect of
risk factors for the association of glucose
status and heart failure were estimated us-
ing linear and logistic regression with age
adjustment. The Mantel-Haenszel
method and logistic regression with age
adjustment was used to estimate odds ra-
tios (ORs). Significance levels are given as
absolute P values if not 0.001.
RESULTS— The overall prevalence of
type 2 diabetes was 3.7% (n  720) and
heart failure 3.8% (n  733) in the total
population of 19,381 participants (Table
1). The prevalence of heart failure in-
creased significantly with the presence of
AGR (P  0.0001) and type 2 diabetes
(P  0.0001) (Fig. 1). The prevalence of
AGR, type 2 diabetes, and heart failure
increased by age. Considering the age-
group 50–65 years only, the prevalence
of AGR remained stable during the study
period (P  0.23), whereas the preva-
lence of type 2 diabetes (P  0.007) in-
creased in the participants aged 50–65
years for both sexes. The prevalence of
heart failure remained stable for men
(from 5.4 to 4.8%, P  0.19) but de-
creased among women (from 4.9 to 3.3%,
P for trend  0.004) at the end of the
study period.
The age-adjusted strength of the asso-
ciation (OR) of heart failure and type 2
diabetes was 2.7 (95% CI 1.9–3.8) for
men and 2.8 (1.9–4.1) for women, while
the strength of the age-adjusted associa-
tion between AGR and heart failure was
1.6 (1.2–2.1) among men and 1.7 (1.2–
2.4) among women. The median age of
men and women was 53 years. The peri-
od-adjusted ORs were 4.8 (2.5–9.0) for
men aged53 years and 2.5 (1.7–3.7) for
men aged 53 years. This difference did
not reach statistical significance (P 
0.08). The corresponding numbers for
women were 3.1 (1.0–8.7) for those53
years and 3.4 (2.3–5.1) for those 53
years (P  0.86).
Table 1—Prevalence of type 2 diabetes, abnormal glucose regulation, and heart failure in the Reykjavík Study
Age-groups (years)
by sex
Total study
population
Normal glucose regulation Abnormal glucose regulation Diabetes
Total With heart failure Total With heart failure Total With heart failure
Male
30–39 540 509 (94.3) 7 (1.3) 25 (4.6) 0 (0) 5 (0.9) 0 (0)
40–49 2,863 2,574 (89.9) 51 (2.0) 214 (7.5) 4 (1.9) 72 (2.5) 9 (12.5)
50–59 4,110 3,482 (84.7) 139 (4.0) 450 (11.0) 30 (6.7) 171 (4.2) 20 (11.7)
60–60 1,226 962 (78.5) 60 (6.2) 183 (14.9) 16 (8.7) 77 (6.3) 7 (9.1)
70 584 401 (68.7) 24 (6.0) 112 (19.2) 14 (12.5) 70 (12.0) 11 (15.7)
All 9,323 7,928 (85.0) 281 (3.5) 984 (10.6) 64 (6.5) 395 (4.2) 47 (11.9)
Female
30–39 593 562 (94.8) 6 (1.1) 27 (4.6) 0 (0) 2 (0.3) 0 (0)
40–49 2,671 2,443 (91.5) 39 (1.6) 189 (7.1) 1 (0.1) 34 (1.3) 2 (5.9)
50–59 4,441 3,878 (87.3) 109 (2.8) 448 (10.1) 27 (6.0) 110 (2.5) 12 (10.9)
60–69 1,530 1,230 (80.4) 59 (4.8) 205 (13.4) 13 (6.3) 91 (6.0) 5 (5.5)
70 823 609 (74.0) 35 (5.7) 124 (15.1) 14 (11.3) 88 (10.7) 19 (21.6)
All 10,058 8,722 (86.7) 248 (2.8) 993 (9.9) 55 (5.5) 325 (3.2) 38 (11.7)
Data are n (%).
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Age, weight, BMI, heart rate, and sys-
tolic and diastolic blood pressure were
highest (P  0.001) in participants hav-
ing both glucose abnormalities and heart
failure, declined in those with either glu-
cose abnormality or heart failure, and
lowest in the reference group. Current
smoking was most prevalent in groups 3
and 4 (P 0.03) and previous smoking in
groups 1 and 2 (P  0.0001). A family
history of diabetes was most common
among participants with type 2 diabetes
(P  0.0001). Cholesterol levels did not
differ significantly among the four groups
with or without glucose abnormalities.
Triglycerides were highest in group 1
(P  0.0001) and free fatty acids in AGR
group 1 (P 0.0001). Sedimentation rate
and uric acid were highest in group 1 and
gradually decreased to the lowest level in
group 4 (P  0.0001).
ECG abnormalities, besides those in-
cluded in the heart failure definition, were
most common in group 1 and declined to
the lowest level in group 4 (P 0.0001).
Treatment with diuretic agents and/or
digitalis, as well as with a nonsteroidal
anti-inflammatory drug, was most fre-
quent in the heart failure group (P 
0.0001).
CONCLUSIONS— The prevalence
of glucose abnormalities and heart failure
increased with age. Heart failure was
found in 11.8% of participants with type
2 diabetes and 6.0% with AGR but only in
3.2% of control subjects. Age, weight,
BMI, heart rate, triglycerides, and systolic
and diastolic blood pressure were signifi-
cant concomitant coronary risk factors in
participants with type 2 diabetes and
heart failure, either combined or as sepa-
rate diseases. The strength of the associa-
tion between heart failure and type 2
diabetes was 2.7 (95% CI: 1.9–3.8) for
men and 2.8 (1.9–4.1) for women and
somewhat lower between AGR and heart
failure (1.6 [1.2–2.1] for men and 1.7
[1.2–2.4] for women).
The diagnostic criteria for heart fail-
ure vary due to acknowledged difficulties
in defining this condition epidemiologi-
cally. The diagnosis is based on a combi-
nation of symptoms and signs of cardiac
disease (12). The protocol for the Reykja-
vı´k Study did not include a heart failure
algorithm, and echocardiography was not
routinely used at the time the study was
initiated. The combination of reported
tiredness and breathlessness and the out-
Figure 1—A: Age-adjusted prevalence of heart failure according to glucose regulation in male ()
and female (f) participants in the Reykjavı´k Study. B: Prevalence of heart failure by age and glucose
abnormalities in men. C: Prevalence of heart failure by age and glucose abnormalities in women.
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come of ECG or chest X-ray provided an
opportunity to diagnose heart failure in
concordance with the present guidelines
issued by the European Society of Cardi-
ology (12). There is still a risk for false-
posit ive and -negative diagnosis.
However, in the Framingham Study,
signs of cardiac dysfunction, such as heart
enlargement on chest X-ray and left ven-
tricular hypertrophy on ECG, were highly
predictive for deteriorating cardiac func-
tion (13). Moreover, only 8 –15% of
asymptomatic people with hypertension,
diabetes, coronary artery disease, or pre-
vious myocardial infarction had systolic
dysfunction when screened with echocar-
diography (14).
During the time of this study, the def-
inition of glucometabolic state was
changed from the use of OGTT to the use
of fasting glucose only. As demonstrated
by the GAMI (Glucose Abnormalities in
Patients with Myocardial Infarction) and
DECODE (Diabetes Epidemiology: Col-
laborative Analysis of Diagnostic Criteria
in Europe) studies (15,16), the use of fast-
ing blood glucose alone will not disclose
people with impaired glucose tolerance
and will miss some cases of diabetes.
Thus, if anything, the present study un-
derestimates the true prevalence of these
conditions and their relations to heart fail-
ure. Another factor of potential impact on
glucose categorization is that this study
used 50 g glucose rather than the cur-
rently used 75 g glucose for OGTTs. This
is, however, compensated by blood sam-
ples taken 1.5 rather than 2 h after glucose
ingestion as currently practiced. Thus, the
potential underestimation should be, at
least to some extent, corrected for by the
timing of the glucose determinations.
A unique strength of this study is the
oral glucose tolerance testing, which of-
fers an opportunity not only to study par-
ticipants with established type 2 diabetes
but also to identify people with newly de-
tected type 2 diabetes or AGR. Moreover,
the large population-based study popula-
tion made it possible to adjust for several
risk factors and for ischemic heart disease.
The prevalence of heart failure was
3–4% in participants with normal glu-
cose metabolism, 6% in those with AGR,
and 12% in those with type 2 diabetes.
The prevalence of heart failure is similar
to that in the Rotterdam Study (6). Amato
et al. (5) studied an elderly Italian popu-
lation and reported a higher prevalence of
heart failure (9.5%), of whom 29.6% had
diabetes. An explanation is the higher age
(74.2 years) in their population. The
prevalence of heart failure combined with
type 2 diabetes increased gradually from
zero in men and women40 years of age
to 14.3 and 22.7%, respectively, in those
70 years of age. Similar observations
were made in the Framingham Study
(17,18). The proportion of AGR in this
study seems to be higher than overt type 2
diabetes in patients with heart failure.
This novel finding underlines that the risk
with hyperglycemia does not begin at lev-
els used as a cutoff for type 2 diabetes. It
supports the suggestion that glucometa-
bolic abnormalities confer risk on a con-
tinuous scale for heart failure (19,20).
Hypertension, coronary artery dis-
ease, and impaired glucose tolerance are
important risk factors for heart failure
(13). Reports from the Medicare study
showed that hypertension was more com-
mon in diabetic patients with heart failure
than in the U.S. census population (21).
Similar results were found in the present
study, where raised blood pressure was
significantly higher in participants with
disturbed glucose regulation and, in par-
ticular, among those with both glucose
abnormalities and heart failure. This is in
accordance with previous reports from
the Reykjavı´k Study underlining the
strong relation between increased levels
of blood glucose and hypertension (22).
The importance of this association is fur-
ther supported by Iribarren et al. (3), who
showed an increase of HbA1c by 1% to be
related to increased risk for heart failure
by 8%.
One may assume that metabolic fac-
tors related to the glucometabolic abnor-
malities negatively influence myocardial
function or that there are common de-
nominators for the development of dis-
turbed glucose regulation and myocardial
dysfunction. Type 2 diabetes and related
conditions are characterized by increased
insulin resistance and/or decreased insu-
lin production. This restricts myocardial
energy production via glucose oxidation.
In contrast, -oxidation of free fatty acids
is enhanced. Myocardial cells are sup-
plied with free fatty acids either from en-
dogenous cardiac triglyceride stores or
exogenous sources in the blood (23). This
is a likely explanation for the increased
levels of triglycerides and free fatty acids
observed in participants with AGR. Inter-
estingly these levels were high not only in
participants with diabetes but also in
those with AGR. The levels were lower in
participants without both glucose abnor-
malities and heart failure and in those
with heart failure only. Free fatty acid ox-
idation is more energy consuming than
glucose oxidation and diminishes aerobic
glycolysis, shifting myocardial metabo-
lism in an anaerobic direction. It has been
proposed that repeated intracellular accu-
mulation of free fatty acids and its metab-
olites may cause myocardial dysfunction
(23).
Another finding in the Reykjavı´k
Study may lead to an alternate explana-
tion of the link between glucometabolic
pertubations and myocardial dysfunc-
tion. Participants with glucose abnormal-
ities and/or heart failure had increased
levels of sedimentation rate, indicating
enhanced inflammatory activity. Young et
al. (24) proposed that metabolic condi-
tions play a significant role in cardiac ad-
aptation and remodelling. This leads to an
increase of myosin heavy chain , altered
troponin T molecules, diminished storage
of creatinine phosphatases, and decreased
sarcoplasmatic ATP-ase activity, which
may result in myocyte hypertrophy asso-
ciated with impaired contractile function
and less effective energy supply (24,25).
Hyperglycemia-induced activation of
protein kinase C may alter the function of
endothelial nitric oxide synthase into su-
peroxide generator, thus producing free
radicals, which are potent stimulators of
programmed cell death, which is substan-
tially enhanced in diabetic hearts (25).
The activation may also act on pancreatic
-cells, thereby further compromising
their function, adding to glucometabolic
disturbance, and strengthening the rela-
tion between myocardial dysfunction and
glucometabolic perturbations.
The prevalence of glucose abnormal-
ities and heart failure increases with age.
The prevalence of heart failure is doubled
in participants with AGR and again dou-
bled in type 2 diabetes. The association of
glucose abnormalities and heart failure is
strong. Glucose abnormalities other than
type 2 diabetes are related to the occur-
rence of heart failure. It may be argued
that such patients should be detected and
intensively treated with glucose-lowering
drugs, with the hope of improving their
risk profile.
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